Cargando…

LINC00839 promotes malignancy of liver cancer via binding FMNL2 under hypoxia

Liver cancer is one of the most common malignant tumors in the world and metastasis is the leading cause of death associated with liver cancer. Hypoxia is a common feature of solid tumors and enhances malignant character of cancer cells. However, the exact mechanisms involved in hypoxia-driven liver...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yangyi, Lin, Hongsheng, Wei, Wei, Kong, Yinzhi, Fang, Qiaoling, Chen, Enran, Liu, Jianghua, Li, Mingfen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637198/
https://www.ncbi.nlm.nih.gov/pubmed/36335129
http://dx.doi.org/10.1038/s41598-022-16972-z
_version_ 1784825132228804608
author Xie, Yangyi
Lin, Hongsheng
Wei, Wei
Kong, Yinzhi
Fang, Qiaoling
Chen, Enran
Liu, Jianghua
Li, Mingfen
author_facet Xie, Yangyi
Lin, Hongsheng
Wei, Wei
Kong, Yinzhi
Fang, Qiaoling
Chen, Enran
Liu, Jianghua
Li, Mingfen
author_sort Xie, Yangyi
collection PubMed
description Liver cancer is one of the most common malignant tumors in the world and metastasis is the leading cause of death associated with liver cancer. Hypoxia is a common feature of solid tumors and enhances malignant character of cancer cells. However, the exact mechanisms involved in hypoxia-driven liver cancer progression and metastasis have not been well clarified so far. The aim of this study was to investigate the contribution of long non-coding RNA (lncRNA) in hypoxia promoting liver cancer progression. We screened and revealed LINC00839 as a novel hypoxia-responsive lncRNA in liver cancer. LINC00839 expression was up-regulated in liver cancer tissues and cell lines, and the patients with high LINC00839 expression had shortened overall survival. LINC00839 further overexpressed under hypoxia and promoted liver cancer cell proliferation, migration, and invasion. Mechanistically, LINC00839 bound multiple proteins that were primarily associated with the metabolism and RNA transport, and positively regulated the expression of Formin-like protein 2 (FMNL2). LINC00839 could promote hypoxia-mediated liver cancer progression, suggesting it may be a clinically valuable biomarker and serve as a molecular target for the diagnosis, prognosis, and therapy of liver cancer.
format Online
Article
Text
id pubmed-9637198
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-96371982022-11-07 LINC00839 promotes malignancy of liver cancer via binding FMNL2 under hypoxia Xie, Yangyi Lin, Hongsheng Wei, Wei Kong, Yinzhi Fang, Qiaoling Chen, Enran Liu, Jianghua Li, Mingfen Sci Rep Article Liver cancer is one of the most common malignant tumors in the world and metastasis is the leading cause of death associated with liver cancer. Hypoxia is a common feature of solid tumors and enhances malignant character of cancer cells. However, the exact mechanisms involved in hypoxia-driven liver cancer progression and metastasis have not been well clarified so far. The aim of this study was to investigate the contribution of long non-coding RNA (lncRNA) in hypoxia promoting liver cancer progression. We screened and revealed LINC00839 as a novel hypoxia-responsive lncRNA in liver cancer. LINC00839 expression was up-regulated in liver cancer tissues and cell lines, and the patients with high LINC00839 expression had shortened overall survival. LINC00839 further overexpressed under hypoxia and promoted liver cancer cell proliferation, migration, and invasion. Mechanistically, LINC00839 bound multiple proteins that were primarily associated with the metabolism and RNA transport, and positively regulated the expression of Formin-like protein 2 (FMNL2). LINC00839 could promote hypoxia-mediated liver cancer progression, suggesting it may be a clinically valuable biomarker and serve as a molecular target for the diagnosis, prognosis, and therapy of liver cancer. Nature Publishing Group UK 2022-11-05 /pmc/articles/PMC9637198/ /pubmed/36335129 http://dx.doi.org/10.1038/s41598-022-16972-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Xie, Yangyi
Lin, Hongsheng
Wei, Wei
Kong, Yinzhi
Fang, Qiaoling
Chen, Enran
Liu, Jianghua
Li, Mingfen
LINC00839 promotes malignancy of liver cancer via binding FMNL2 under hypoxia
title LINC00839 promotes malignancy of liver cancer via binding FMNL2 under hypoxia
title_full LINC00839 promotes malignancy of liver cancer via binding FMNL2 under hypoxia
title_fullStr LINC00839 promotes malignancy of liver cancer via binding FMNL2 under hypoxia
title_full_unstemmed LINC00839 promotes malignancy of liver cancer via binding FMNL2 under hypoxia
title_short LINC00839 promotes malignancy of liver cancer via binding FMNL2 under hypoxia
title_sort linc00839 promotes malignancy of liver cancer via binding fmnl2 under hypoxia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637198/
https://www.ncbi.nlm.nih.gov/pubmed/36335129
http://dx.doi.org/10.1038/s41598-022-16972-z
work_keys_str_mv AT xieyangyi linc00839promotesmalignancyoflivercancerviabindingfmnl2underhypoxia
AT linhongsheng linc00839promotesmalignancyoflivercancerviabindingfmnl2underhypoxia
AT weiwei linc00839promotesmalignancyoflivercancerviabindingfmnl2underhypoxia
AT kongyinzhi linc00839promotesmalignancyoflivercancerviabindingfmnl2underhypoxia
AT fangqiaoling linc00839promotesmalignancyoflivercancerviabindingfmnl2underhypoxia
AT chenenran linc00839promotesmalignancyoflivercancerviabindingfmnl2underhypoxia
AT liujianghua linc00839promotesmalignancyoflivercancerviabindingfmnl2underhypoxia
AT limingfen linc00839promotesmalignancyoflivercancerviabindingfmnl2underhypoxia